Meyka Pro banner
DarioHealth Corp.

DarioHealth Corp. Fundamental Analysis (NASDAQ: DRIO)

DRIONASDAQ
HealthcareMedical - Diagnostics & Research
$7.49
$0.32(4.46%)
U.S. Market opens in 64h 6m

DarioHealth Corp. Fundamental Analysis (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) shows weak financial fundamentals with a PE ratio of 10.64, profit margin of 3.23%, and ROE of 1.04%. The company generates $0.0B in annual revenue with weak year-over-year growth of -17.31%.

Key Strengths

Cash Position20.37%
PEG Ratio0.11
Current Ratio2.31

Areas of Concern

ROE1.04%
Operating Margin-3.29%
We analyze DRIO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 25.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
25.2/100

We analyze DRIO's fundamental strength across five key dimensions:

Efficiency Score

Excellent

DRIO demonstrates superior asset utilization.

ROA > 10%
70.17%

Valuation Score

Excellent

DRIO trades at attractive valuation levels.

PE < 25
10.64
PEG Ratio < 2
0.11

Growth Score

Weak

DRIO faces weak or negative growth trends.

Revenue Growth > 5%
-17.31%
EPS Growth > 10%
-9.46%

Financial Health Score

Excellent

DRIO maintains a strong and stable balance sheet.

Debt/Equity < 1
0.59
Current Ratio > 1
2.31

Profitability Score

Weak

DRIO struggles to sustain strong margins.

ROE > 15%
104.15%
Net Margin ≥ 15%
3.23%
Positive Free Cash Flow
No

Key Financial Metrics

Is DRIO Expensive or Cheap?

P/E Ratio

DRIO trades at 10.64 times earnings. This suggests potential undervaluation.

10.64

PEG Ratio

When adjusting for growth, DRIO's PEG of 0.11 indicates potential undervaluation.

0.11

Price to Book

The market values DarioHealth Corp. at 1.24 times its book value. This may indicate undervaluation.

1.24

EV/EBITDA

Enterprise value stands at -0.94 times EBITDA. This is generally considered low.

-0.94

How Well Does DRIO Make Money?

Net Profit Margin

For every $100 in sales, DarioHealth Corp. keeps $3.23 as profit after all expenses.

3.23%

Operating Margin

Core operations generate -3.29 in profit for every $100 in revenue, before interest and taxes.

-3.29%

ROE

Management delivers $1.04 in profit for every $100 of shareholder equity.

1.04%

ROA

DarioHealth Corp. generates $70.17 in profit for every $100 in assets, demonstrating efficient asset deployment.

70.17%

Following the Money - Real Cash Generation

Operating Cash Flow

DarioHealth Corp. generates limited operating cash flow of $-19.37M, signaling weaker underlying cash strength.

$-19.37M

Free Cash Flow

DarioHealth Corp. generates weak or negative free cash flow of $-19.48M, restricting financial flexibility.

$-19.48M

FCF Per Share

Each share generates $-2.66 in free cash annually.

$-2.66

FCF Yield

DRIO converts -47.38% of its market value into free cash.

-47.38%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

10.64

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.11

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.24

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.56

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.59

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.31

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.04

vs 25 benchmark

ROA

Return on assets percentage

0.70

vs 25 benchmark

ROCE

Return on capital employed

-0.79

vs 25 benchmark

How DRIO Stacks Against Its Sector Peers

MetricDRIO ValueSector AveragePerformance
P/E Ratio10.6431.19 Better (Cheaper)
ROE104.15%447.00% Weak
Net Margin322.77%21592.00% Weak
Debt/Equity0.590.54 Neutral
Current Ratio2.315.66 Strong Liquidity
ROA70.17%-52.00% (disorted) Strong

DRIO outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DarioHealth Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-64.54%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

82.98%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

82.43%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ